FOLH1 and posterior cortical atrophy: As a consequence, in case of patients who have a rising PSA after primary therapy and should be under observation due to low-risk characteristics (e.g., elderly, low PSA, long PSAdt, low ISUP) [29], the presence of negative PSMA-PET scan might strengthen this decision as the likelihood of relevant events during follow-up might be lower (except for those PCa with low PSMA expression).